Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FFNP Breast PET/MRI for Early Response to Presurgical Endocrine Therapy in Breast Cancer
NCT06086704Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluorofuranylnorprogesterone in breast cancer (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Percentage change in 18F-FFNP uptake between baseline and follow-up PET/MRI scans at 7 weeks and Percentage change in tumor Ki67 proliferation score at 7 weeks. Started Sep 2024; status: recruiting.
02
Drugs
fluorofuranylnorprogesterone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06086704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086704.